We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
Researchers have found that coronaviruses like SARS-CoV-2 contain genes that appear important for viral survival even though they don't produce a working protein. Their work investigating how these ...
The Sheffield, England-based company is selling Benchmark Genetics Ltd and Benchmark Genetics Norway AS to Starfish Bidco AS, a wholly owned subsidiary of Novo Holdings AS, for an enterprise value of ...